IMNN: R&D Day Highlights IMNN-001 Data in Frontline Ovarian Cancer
On September 23, 2026, Imunon, Inc. (IMNN) held an R&D day to review the results for the IMNN-001 program in newly diagnosed advanced ovarian...
92 Views
IMNN: Strong Enrollment Momentum Continuing for Phase 3 OVATION 3 Trial
On August 11, 2026, Imunon, Inc. (IMNN) announced financial results for the second quarter of 2026 and provided a business update. The company is...
93 Views
Primer: Imunon (IMNN US) - Aug 2026
Imunon is a clinical-stage biotechnology company whose value is primarily driven by its lead candidate, IMNN-001, a novel DNA-based...
91 Views
IMNN: 10 Million Financing to Advance Phase 3 OVATION 3 Trial
On June 4, 2026, Imunon, Inc. (IMNN) announced a financing that is expected to provide up to $10 million in aggregate proceeds. The financing...
93 Views
IMNN: On Track to Have 80 Patients Enrolled in Phase 3 OVATION 3 Trial by 1Q27
On May 12, 2026, Imunon, Inc. (IMNN) announced financial results for the first quarter of 2026 and provided a business update. The company...
91 Views